Fulcrum Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Fulcrum Therapeutics

11/11/2024 15:38

* Fulcrum Therapeutics Inc  FULC.OQ   FULC.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
13 for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Fulcrum Therapeutics Inc
is
for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fulcrum
Therapeutics Inc is $4.00​, above​ its last closing price
of $3.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  0.02        -0.01      0.87      Beat    7,060
 Mar. 31 2024  -0.44       -0.44      -0.43     Beat    1.7
 Dec. 31 2023  -0.42       -0.43      -0.40     Beat    6​
 Sep. 30 2023  -0.43       -0.43      -0.39     Beat    10.3
 ​​Jun.        -0.45       -0.44      -0.38     Beat    14.5
 30 2023                                                
 Mar. 31 2023  -0.47       -0.46      -0.41     Beat    10​
 Dec. 31 2022  -0.51       -0.49      -0.50     Missed  -2.1
 Sep. 30 2022  -0.62       -0.61      -0.51     Beat    16.7
 This summary was machine generated November 11 at 15:37 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)